SlideShare is now on Android. 15 million presentations at your fingertips.  Get the app

×
  • Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 

Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner

by Working at Reports Corner on Apr 27, 2013

  • 454 views

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good ...

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates.

https://www.reportscorner.com/reports/10015/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Japan-Pharma/

Statistics

Views

Total Views
454
Views on SlideShare
454
Embed Views
0

Actions

Likes
0
Downloads
8
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via SlideShare as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
Post Comment
Edit your comment

Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner Global pharmaceutical & biotechnology outlook 2013 japan pharma - Reports Corner Presentation Transcript